久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

AstraZeneca ups R&D localization

By Zheng Yiran | China Daily | Updated: 2018-12-04 11:00
Share
Share - WeChat
A man walks past an AstraZeneca site in Macclesfield, north England. [Photo/Agencies]

Global biopharmaceutical giant AstraZeneca PLC is promoting the research and development of seven medicines in China, as the company endeavors to strengthen its local R&D capabilities to lower costs for patients.

According to the company, it will take advantage of its production and logistics bases in Wuxi and Taizhou in Jiangsu province to mass produce high-quality and low-cost medicines.

"In addition to the Chinese market, we supply over 70 countries around the world, mainly developing countries. We will use our production advantages to raise production and lower costs, so that patients can benefit from more reasonable prices," said Wang Lei, CEO of AstraZeneca China.

At the China International Import Expo, the Cambridge, United Kingdom-headquartered company demonstrated roughly 30 innovative products that it had brought to China since entering the country 25 years ago. A renal anemia medication, which is being developed locally in China, was displayed at the expo. The drug is set to make its global debut in China next year.

According to Wang, AstraZeneca hopes to bring its global experience to China through the CIIE. The company hopes to integrate its experience with China's successful internet of things ecosystem, colliding with more creative sparks, to meet the country's ever-changing and upgrading medical needs and pain points, by bringing new solutions for Chinese patients, he said.

Wang said China has evolved into the company's second-largest market. As the second-largest medical consumption market in the world, China is also the company's fastest-growing market, with 12 percent year-on-year growth in 2017, he said.

Company statistics show sales revenues stood at $22.5 billion in 2017, of which $2.96 billion was from China, 13.2 percent of the total.

That makes AstraZeneca the second-largest multinational pharmaceutical company in China. To date, it has invested more than $750 million into R&D of medicines that improve people's quality of life

Having operated in China for 25 years, the company continuously adjusts its development strategy, and is beginning to place a heavier emphasis on local R&D innovation.

"In the past, we merely brought foreign drugs into China. From now on, we will develop new drugs locally in China, and bring the products not only to Chinese patients, but also patients from other developing countries. China's innovative drug imports and market access are accelerating. This shifts our emphasis onto specific medicines and anti-cancer drugs," Wang said.

For AstraZeneca, R&D localization is an important opportunity for multinational pharmaceutical companies, leading it to promote the R&D process of seven new drugs in China.

The innovative products and development models based in China can also be applied to other markets, says the company.

"The innovative business model in China will not only stay in China. After being applied to various therapeutic fields, the model can be used in other markets. In the future, governments and medical institutions in other countries will rush to embrace Chinese innovation, and that era is coming soon," Wang said.

Yang Wenya, a medical analyst with Beijing-headquartered think tank EO Intelligence, said: "For medical companies, local innovation in developing new medicines takes advantage of the local production advantages to cut costs and raise efficiency, throughout the process of R&D, production and transportation. In this way, both medical companies and patients benefit. This is an inevitable trend of the international division of labor."

She said China's large patient pool offers abundant resources for clinical research and data is easy to access.

"Producing medicine locally saves the cost of transporting medicines. Also, the two major production logistics bases in Wuxi and Taizhou have obvious agglomeration and scale effects, which can guarantee the quality and quantity of drugs," Yang said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产高清在线看 | 国产成人在线免费视频 | 夜夜操夜夜爽 | 欧美一级视 | 免费人成综合在线视频 | 久久久久久全国免费观看 | 亚洲午夜久久久久影院 | 日本三片在在线播放 | 免费视频观看在线www日本 | 91www成人久久 | 午夜不卡在线 | 在线观看精品国产 | 成年人网站在线观看免费 | 99re这里只有精品99 | 亚洲一区二区三区精品视频 | 欧美成人亚洲欧美成人 | 一级做a爰全过程免费视频毛片 | 美国第一毛片 | 美女午夜色视频在线观看 | 亚洲欧美国产高清va在线播放 | 国产精品深爱在线 | 免费精品久久久视频 | 亚洲综合第一欧美日韩中文 | 在线中文字幕精品第5页 | 久久免费观看视频 | 久久一二 | 黄色国产在线观看 | 亚洲国产高清一区二区三区 | 日韩毛片在线播放 | 美女黄频免费观看 | 男女午夜爽爽 | 大学生久久香蕉国产线观看 | 亚洲人成综合网站在线 | 国产一级在线观看视频 | 亚洲欧美在线观看播放 | 在线观看精品视频一区二区三区 | 成人国产在线观看 | 中文字幕波多野不卡一区 | 国产一区二区三区免费视频 | 亚洲三级一区 | 日本一本久道 |